Nociceptin/orphanin FQ receptor ligands

被引:79
作者
Calo, G
Bigoni, R
Rizzi, A
Guerrini, R
Salvadori, S
Regoli, D
机构
[1] Univ Ferrara, Pharmacol Sect, Dept Expt & Clin Med, I-44100 Ferrara, Italy
[2] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy
[3] Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy
关键词
nociceptin; orphanin FQ; nociceptin orphanin FQ receptor; receptor ligands; agonists and antagonists; pharmacological assays;
D O I
10.1016/S0196-9781(00)00230-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nociceptin (NC), alias Orphanin FQ (OFQ) is a heptadecapeptide structurally related to opioid peptides, especially Dynorphin A, which, however, does not interact with classic opioid receptors. NC selectively activates its own receptor (OP4), which has been shown to be insensitive to the naturally occurring opioid peptides as well as to a large number of non-peptide opioid receptor ligands, including naloxone. Thus, the NC/OP4 system represents a new peptide-based signaling pathway, which is pharmacologically distinct from the opioid systems. The pharmacological tools available for investigating NC actions are at present rather limited and include: I)peptide ligands obtained from structure activity studies performed using NC(1-13)NH2 as a template or discovered by screening peptide combinatorial libraries; 2) nonpeptide ligands that are either molecules already known to interact with classic opioid receptors or novel molecules designed and synthesized as selective ligands of the OP4 receptor. In the present paper the functional data obtained from both in vitro and in vivo studies with each relevant OP4 receptor ligand will be analyzed and discussed comparing the advantages and disadvantages of each molecule. We hope that the present work will aid investigators, working in the NC/OP4 field, in the choice of the pharmacological tools suitable fur their experiments. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:935 / 947
页数:13
相关论文
共 100 条
  • [1] Abdulla FA, 1998, J NEUROSCI, V18, P9685
  • [2] Albrecht E, 1998, J PHARMACOL EXP THER, V286, P896
  • [3] Allen CN, 1999, J NEUROSCI, V19, P2152
  • [4] Nociceptin/orphanin FQ dilates pial arteries by KATP and Kca channel activation
    Armstead, WM
    [J]. BRAIN RESEARCH, 1999, 835 (02) : 315 - 323
  • [5] The stereoselective κ-opioid receptor antagonist Mr2266 does not exhibit stereoselectivity as an antagonist at the orphan opioid (ORL1) receptor
    Bauer, U
    Nakazi, M
    Kathmann, M
    Göthert, M
    Schlicker, E
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (01) : 17 - 20
  • [6] Ligands for κ-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library
    Becker, JAJ
    Wallace, A
    Garzon, A
    Ingallinella, P
    Bianchi, E
    Cortese, R
    Simonin, F
    Kieffer, BL
    Pessi, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) : 27513 - 27522
  • [7] Nociceptin binding sites in frog (Rana esculenta) brain membranes
    Benyhe, S
    Menory, K
    Farkas, J
    Tóth, G
    Guerrini, R
    Salvadori, S
    Orosz, G
    Wollemann, M
    Borsodi, A
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 260 (03) : 592 - 596
  • [8] Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin orphanin FQ
    Berger, H
    Albrecht, E
    Wallukat, G
    Bienert, M
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (03) : 555 - 558
  • [9] BERGER H, 1999, REGUL PEPTIDES, V80, P122
  • [10] Nociceptin and the ORL-1 ligand [Phe1ψ (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain
    Bertorelli, R
    Corradini, L
    Rafiq, K
    Tupper, J
    Calò, G
    Ongini, E
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (06) : 1252 - 1258